Jaguar Health, Inc. (JAGX) Form 424B5 — Nov 9, 2026
Jaguar Health filed a 424B5 prospectus supplement for a new $75 million at-the-market offering of common stock through Ladenburg Thalmann, on top of roughly $104 million already sold under prior ATM registrations. The offering is priced off a $0.4988 closing price, and a full draw would grow shares outstanding from about 13.3 million to about 163.7 million — more than 12x the current share count. The filing comes shortly after a 1-for-15 reverse stock split (September 2026) and a string of dilutive preferred/note exchanges with Streeterville and Lincoln Alternative Strategies, underscoring that this capital raise is a survival necessity rather than opportunistic.
Key figures
- Gross Proceeds
- 75000000
- Offering Price
- 0.4988
- Shares Outstanding
- 13,345,986 prior; 163,706,852 after full sale at $0.4988
- Commission
- 3% of gross sales price
- Reverse split ratio
- 1-for-15 (effective September 17, 2026)
- Dilution to new investors
- $0.03 per share
- Estimated offering expenses
- $385,000 plus $75,000 counsel reimbursement
- Series p redemption obligation
- 10% of ATM net proceeds must redeem Series P Preferred Stock
- Net tangible book value june 2026
- $(10.2) million or $(31.39) per share
- Prior atm sales 2021 registration
- $71.8 million
- Prior atm sales 2024 registration
- $32.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.